
Xiang-Ming Lao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6027777/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. Cancer Discovery, 2016, 6, 546-559.	7.7	253
2	Transforming growth factor-l²1-induced epithelial–mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Letters, 2014, 354, 320-328.	3.2	88
3	The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. Journal of Clinical Investigation, 2019, 129, 3347-3360.	3.9	82
4	Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice. Gastroenterology, 2019, 156, 1890-1904.e16.	0.6	79
5	Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver International, 2013, 33, 595-604.	1.9	78
6	Chemokine (Câ€Xâ€C motif) receptor 3–positive B cells link interleukinâ€17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma. Hepatology, 2015, 62, 1779-1790.	3.6	78
7	Primary Carcinosarcoma of the Liver: Clinicopathologic Features of 5 Cases and a Review of the Literature. American Journal of Surgical Pathology, 2007, 31, 817-826.	2.1	76
8	Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. Nature Communications, 2016, 7, 13453.	5.8	68
9	Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization. Cancer Discovery, 2016, 6, 1182-1195.	7.7	65
10	B7-H1–expressing antigen-presenting cells mediate polarization of protumorigenic Th22 subsets. Journal of Clinical Investigation, 2014, 124, 4657-4667.	3.9	65
11	A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. OncoImmunology, 2016, 5, e1083671.	2.1	56
12	Peritumoral monocytes induce cancer cell autophagy to facilitate the progression of human hepatocellular carcinoma. Autophagy, 2018, 14, 1335-1346.	4.3	53
13	Peritumoral stromal neutrophils are essential for c-Met-elicited metastasis in human hepatocellular carcinoma. Oncolmmunology, 2016, 5, e1219828.	2.1	47
14	Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatology Research, 2011, 41, 553-563.	1.8	42
15	Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis. BMC Cancer, 2015, 15, 64.	1.1	32
16	Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC Cancer, 2015, 15, 707.	1.1	28
17	Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection. Chinese Journal of Cancer, 2016, 35, 28.	4.9	26
18	Transarterial chemoembolization combined with recombinant human adenovirus typeÂ5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chinese Journal of Cancer, 2017, 36, 59.	4.9	24

XIANG-MING LAO

#	Article	IF	CITATIONS
19	B cells polarize pathogenic inflammatory T helper subsets through ICOSL-dependent glycolysis. Science Advances, 2020, 6, .	4.7	22
20	Impact of oral anti–hepatitis B therapy on the survival of patients with hepatocellular carcinoma initially treated with chemoembolization. Chinese Journal of Cancer, 2015, 34, 205-16.	4.9	17
21	Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment. Digestive Diseases and Sciences, 2016, 61, 2465-2476.	1.1	13
22	Hepatocellular carcinoma with en bloc diaphragmatic resection: A single-center experience over 14 years. International Journal of Surgery, 2018, 53, 93-97.	1.1	11
23	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
24	A gastrointestinal stromal tumor of the jejunum associated with intrahepatic cholangiocarcinoma and pulmonary hamartoma: A case report. Acta Oncológica, 2009, 48, 934-937.	0.8	7
25	Clinical conditions and treatment requirements for longâ€term survival among hepatitis Bâ€related hepatocellular carcinoma initially treated with chemoembolization. Cancer Medicine, 2019, 8, 5097-5107.	1.3	7
26	Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2019, 64, 2187-2198.	1.1	6
27	Impact of overweightness and critical weight loss on overall survival in patients with hepatocellular carcinoma initially treated with chemoembolization. Gastroenterology Report, 2020, 8, 125-133.	0.6	5
28	Clinical practice of basin-shaped hepaticojejunostomy following hilar resection of stage III/IV hilar cholangiocarcinoma. BMC Gastroenterology, 2019, 19, 99.	0.8	4
29	Hepatitis <scp>B</scp> virus reactivation and liver function after chemoembolization for hepatocellular carcinoma: How is it different from systemic chemotherapy?. Asia-Pacific Journal of Clinical Opeology, 2013, 9, 381-382	0.7	3